Χαιρετισμός του Προέδρου του ΕΚΕΦΕ «Δημόκριτος»

Transcript

1 Bio & Abstract Book

2 2 Χαιρετισμός του Προέδρου του ΕΚΕΦΕ «Δημόκριτος» Σας καλωσορίζω στο 1 ο Hellenic Forum for Science, Technology and Innovation, το οποίο φιλοδοξεί να καταστήσει τον «Δημόκριτο» κέντρο συνεργασίας (hub) μεταξύ της ελληνικής ερευνητικής κοινότητας και διακεκριμένων Ελλήνων επιστημόνων της διασποράς. H Ελλάδα, όπως το Ισραήλ, η Κίνα και άλλες χώρες διαθέτουν εξαιρετικά πολυάριθμες και ισχυρές επιστημονικές κοινότητες στο εξωτερικό. Η διαφορά είναι ότι οι άλλες χώρες έχουν αναπτύξει αποτελεσματικά προγράμματα διασύνδεσης και εκμετάλλευσης της τεχνογνωσίας των επιστημόνων της διασποράς. Στην Ελλάδα η διασύνδεση αυτή είναι πολύ περιορισμένη, παρά το γεγονός ότι τα οφέλη τόσο για την περεταίρω ενίσχυση της επιστημονικής αριστείας των ελληνικών ερευνητικών κέντρων, όσο και την ανάπτυξη της καινοτομίας και της εγχώριας τεχνογνωσίας θα ήταν εξαιρετικά σημαντική, δεδομένου ότι οι χιλιάδες Έλληνες διαπρέπουν στα πανεπιστήμια και ερευνητικά κέντρα του εξωτερικού, ενώ πολλοί από αυτούς κατέχουν ηγετικές θέσεις σε επιχειρήσεις του εξωτερικού (Ανδρέας Λιβέρης, πρόεδρος της Dow κλπ.) Mε την οργάνωση του 1 st Hellenic Forum for Science, Technology and Innovation φιλοδοξούμε, όπως προανέφερα, ο «Δημόκριτος» να καταστεί Κέντρο συνεργασίας (hub) των διακεκριμένων Ελλήνων επιστημόνων της διασποράς με ανάπτυξη σχημάτων συνεργασίας ανάλογων του Ισραήλ και της Κίνας και διπλό στόχο, αφενός την περαιτέρω ενίσχυση της επιστημονικής αριστείας, αφετέρου τη μετατροπή της επιστημονικής αριστείας σε «μοχλό ανάπτυξης». Ο δεύτερος στόχος είναι ιδιαίτερα σημαντικός καθώς με τη σημερινή πρωτοφανή οικονομική κρίση καθίσταται επιτακτική η ανάγκη για την αξιοποίηση των ερευνητικών κέντρων ως επιταχυντών αξιοποίησης της πνευματικής ιδιοκτησίας. Για τον λόγο αυτό ο Δημόκριτος παράλληλα με την περαιτέρω ενίσχυση της επιστημονικής αριστείας, έχει καταθέσει ένα ολοκληρωμένο για την δημιουργία του Metropolitan Innovation Campus at Demokritos, μίας «Τεχνόπολης» προσαρμοσμένης στις οικονομικές δυνατότητες της χώρας με κύριο στόχο την προώθηση ιδεών από το εργαστήριο στην αγορά, τη δημιουργία εταιρειών έντασης γνώσης, που θα έχει ως αποτέλεσμα τη δημιουργία θέσεων εργασίας για νέους επιστήμονες, και βέβαια την προσέλκυση επενδύσεων. Αξίζει εδώ να τονίσω ότι η μετατροπή της επιστημονικής αριστείας σε προϊόντα υψηλής τεχνογνωσίας και η ανάπτυξη εταιρειών έντασης γνώσης είναι εξαιρετικά δυσχερής η σχεδόν αδύνατη για την Ελλάδα και για τις χώρες της Νότιας Ευρώπης. Απαιτείται αλλαγή νοοτροπίας, οπότε η συμβολή των Ελλήνων επιστημόνων της διασποράς μπορεί αποβεί ιδιαίτερα σημαντική και στον νευραλγικό αυτό τομέα, αφού στην πλειοψηφία τους διαθέτουν πολύτιμη πείρα στην εφαρμογή ολοκληρωμένων σχεδίων εκμετάλλευσης της πνευματικής ιδιοκτησίας στα ακαδημαϊκά ιδρύματα στα οποία εργάζονται.

3 3 To Hellenic Forum for Science, Technology and Innovation θα οργανώνεται σε ετήσια βάση. Κατά τη διάρκειά του, διακεκριμένοι έλληνες επιστήμονες του εξωτερικού θα δίνουν διαλέξεις και θα παρουσιάζουν το έργο τους ενώ παράλληλα, θα καταθέτουν την άποψή τους για την ανάπτυξη της καινοτομίας στην Ελλάδα. Βασικός στόχος μας είναι η ενίσχυση της επιστημονικής αριστείας με την ανάπτυξη στενών δεσμών με εργαστήρια διακεκριμένων Ελλήνων του εξωτερικού, για παράδειγμα, μέσω οργανωμένων προγραμμάτων «αντίστροφων μετακινήσεων» σε εργαστήρια των διακεκριμένων Ελλήνων καθηγητών του εξωτερικού ή εκπόνησης διδακτορικών διατριβών στον «Δημόκριτο» από κοινού με Πανεπιστήμια στις ΗΠΑ (τα 2 πρώτα χρόνια της διδακτορικής διατριβής σε Αμερικανικά πανεπιστήμια και τα 2 τελευταία στον Δημόκριτο). Ιδιαίτερη έμφαση θα δοθεί στην οργάνωση ειδικών συνεδριάσεων (panels) με θέμα την ακολουθητέα πολιτική στο θέμα της αξιοποίησης των ερευνητικών αποτελεσμάτων μέσω της ανάπτυξης εταιρειών έντασης γνώσης και της αύξησης των πατέντων, δραστηριότητες που στόχο έχουν να συμβάλουν στη μείωση του brain drain και κατ επέκταση, στη μετατροπή των ερευνητικών κέντρων σε «μοχλούς ανάπτυξης». Παράλληλα άρχισε η λειτουργία μόνιμης έκθεσης τεχνολογικών επιτευγμάτων του Δημόκριτου, των εταιρειών του Δημόκριτου και άλλων ερευνητικών κέντρων με στόχο την προσέλκυση επενδύσεων και την ανάπτυξη εγχώριας τεχνογνωσίας. Αυτό που επιδιώκουμε αναλαμβάνοντας τέτοιες πρωτοβουλίες είναι οι προτάσεις των διακεκριμένων Ελλήνων επιστημόνων της διασποράς και τα συμπεράσματα του πρώτου Hellenic Forum for Science, Technology and Innovation καθώς και όσων θα ακολουθήσουν, να χρησιμοποιηθούν από την πολιτεία με τρόπο εποικοδομητικό, ανάλογο αυτού που χρησιμοποιείται για τις προτάσεις «επιτροπών σοφών» για την χάραξη ερευνητικής και αναπτυξιακής πολιτικής σε προηγμένες χώρες. Δρ. Νίκος Κανελλόπουλος Διευθυντής & Πρόεδρος Δ.Σ. του ΕΚΕΦΕ «Δημόκριτος»

4 4 Τετάρτη 17 Ιουλίου 2013 SESSION 1 Συντονιστής: Αντιπρόεδρος Δ.Σ. ΕΚΕΦΕ «Δ» 15:30 Developing agonists of neurotrophin receptors with neuroprotective and neurogenic actions Prof. Achilleas Gravanis Dept. of Pharmacology, School of Medicine, University of Crete, IESL-FORTH 16:00 Novel technologies for blood purification Assoc. Prof. Dimitrios Stamatialis University of Twente 16:30 Σήμα μετάδοσης γλυκοκορτικοειδών: κλινικές προεκτάσεις Καθηγ. Γεώργιος Χρούσος Ιατρική Σχολή, Πανεπιστήμιο Αθηνών

5 5 DEVELOPING AGONISTS OF NEUROTROPHIN RECEPTORS WITH NEUROPROTECTIVE AND NEUROGENIC ACTIONS Prof. Achilleas Gravanis Dept. of Pharmacology, School of Medicine, University of Crete, IESL-FORTH Abstract Neurotrophins control neuronal cell fate and function during development and adulthood. They act through tyrosine kinase Trk and pan-neurotrophin p75ntr receptors, exerting potent neuroprotective and neurogenic effects. However, their potential therapeutic usefulness in neurodegenerative conditions is compromised by their polypeptide nature and their inability to pass through the blood-brain barrier (BBB). We have recently shown that neurosteroid dehydroepiandrosterone (DHEA) prevents neuronal apoptosis (Charalampopoulos et al, PNAS 2004), through binding to TrkA and p75ntr receptors (Lazaridis et al, PLoS Biol 2011), activating prosurvival kinases and anti-apoptotic Bcl-2 proteins, preventing thus the apoptotic loss of NGF receptor positive sensory in NGF null mice. However, DHEA is metabolized in vivo to sex steroids, affecting the endocrine system. We have recently synthesized 17-spiro analogs of DHEA with anti-apoptotic, neuroprotective properties (IC50 at nanomolar levels), deprived of androgenic-estrogenic actions (Calogeropoulou et al, J Med Chem 2009). Synthetic DHEA derivative BNN27 interacts with NGF receptors, TrkA and p75ntr at nanomolar concentrations, been ineffective in TrkB or TrkC receptors. BNN27 regulates TrkA internalization and induces TrkA tyrosine phosphorylation, affecting downstream signaling of Akt and MAPKs in sympathetic neurons. Moreover, BNN27 was shown to promote the interaction of p75ntr receptors with its effector factors RhoGDI, RIP2 and TRAF6. It also partially reverses apoptosis of NGFdependent embryonic sensory neurons of NGF null mice. BNN27 exerts potent neuroprotective and neuroimmunomudulatory effects in a number of experimental animal models of neurodegenerative diseases, such as retina detachment and degeneration in diabetes and ischemia or allergic enecephalomyelitis. The neurogenic properties of BNN27 are also tested in 2D and 3D-collagen cultures of embryonic and adult neural stem cells. BNN derivatives may serve as lead molecules to develop BBB permeable, neurotrophin-like small molecules (microneurotrophins) with potential applications in the treatment of neurodegenerative diseases and brain trauma (Gravanis et al, Science Signaling 2012). Short CV Achilleas Gravanis, Professor of Pharmacology, School of Medicine, University of Crete, Collaborating Researcher at Foundation of Research & Technology-Hellas (IESL-FORTH). He obtained his Diploma in Pharmacy from the University of Athens (1980), his PhD in Pharmacology (1983) from the University Pierre Marie Curie, Paris 6. He worked as a postdoctoral fellow at the Mount Sinai School of Medicine NY ( ). Dr Gravanis served as vice-president of the Hellenic Pharmacological Society, and the Hellenic Biochemical Society, member of the steering committee of the European Pharmacology Network. He was a member of the Fellowships Committee of FEBS and participated as Chairman and member in numerous research committees of the European Union, including the Programme Committee of Framework Programmes FP6 and FP7. He serves as the Chairman of Biosciences Committee of the Hellenic Research & Technology Council. He is a member of the Hellenic Council of Public Health. He published 120 papers in peer-reviewed journals, cited in PubMed (h index: 32, ( He is the co-founder of startup company, Bionature EA Ltd.

6 6 Novel technologies for blood purification Prof. Dr. Dimitrios Stamatialis University of Twente, MIRA Institute of Biomedical Technology and Technical Medicine, Faculty of Science and Technology, Department of Biomaterials Science and Technology, P.O Box 217, 7500 AE Enschede, The Netherlands, Abstract The number of patients with End Stage Renal Disease (ESRD) is progressively increasing and the need for renal replacements therapies is expanding. Worldwide, over 2 million patients suffer from ESRD and each year that number grows by 5%. As transplant options are limited, approximately 70% of patients receive (hemodialysis and peritoneal) dialysis treatments [1]. Despite the high health care costs of dialysis treatment (in the Netherlands over Euro per patient per year), dialysis is only partially successful in the treatment of patients with ESRD. Mortality (15-20% per year) and morbidity of these patients remain excessively high, whereas their quality of life is dismally low. Current hemodialysis (HD) therapy achieves insufficient removal of toxins (mainly removes small, non-protein bound substances by diffusion, leaving toxic larger middle-sized molecules and protein-bound uremic toxins untouched). In addition, inadequate volume and blood pressure control, due to the intermittent character of HD contributes to the high mortality in dialysis patients. Continuous treatment (for example using a portable system) or increased frequency and duration may contribute to gradual removal of excess fluids and improve clearance of uremic waste, potassium and phosphate. In this presentation we will discuss two concepts for achieving prolonged and effective patient treatment: (i) the mixed matrix membrane which combines dialysis with adsorption in one step [2] and (ii) a bioartificial kidney system which combines artificial membranes with kidney cells. The presented research is part of the initiative of the Dutch Kidney Foundation for the development of a portable kidney device, which is expected to lead to significant improvement of quality of life of kidney patients. Literature 1. Medical applications of membranes, Drug delivery, artificial organs and tissue engineering, D.F Stamatialis B.J. Papenburg, M. Gironés, S. Saiful, N.M.S. Bettahalli, S. Schmitmeier and M. Wessling, J. Membr. Sci., 308 (2008) A novel approach for blood purification: mixed matrix membranes combining diffusion and adsorption in one step, M.S.L. Tijink, M. Wester, J. Sun, A. Saris, L.A.M. Bolhuis- Versteeg, S. Saiful, J.A. Joles, Z. Borneman, M. Wessling, D.F. Stamatialis, Acta Biomaterialia 8 (2012)

7 7 CURRICULUM VITAE Date and place of Birth: 21 / 01 / 1968, Sarti - Halkidiki, Greece. Current address: University of Twente, MIRA institute for biomedical engineering and technical medicine, Faculty of Science and Technology, Department of biomaterials science and technology, P.O. Box 217, 7500 AE Enschede, The Netherlands. Tel: ; d.stamatialis@utwente.nl. Selected recent employment activities January 2011 present date: Associate professor, Biomaterials Science and Technology department, MIRA institute of Biomedical Engineering and Technical Medicine, Faculty of Science and Technology, University of Twente The Netherlands. March 2002 December 2010: Assistant / associate professor, Membrane Technology, Faculty of Science and Technology of the University of Twente The Netherlands. March 2000 February 2002: Senior researcher in the European Membrane Institute Twente (EMI Twente) University of Twente The Netherlands. Research interests He supervises research related to biomedical membranes and bio-artificial organs (please check: /. He is the author of more than 90 scientific papers and inventor of 7 patents. Selected recent international activities 2014: Scheduled research visit at the Renal Research Institute (March June 2014, New York USA). 2013: Research visit at the nephrology department of the San Bortolo Hospital (June 2013, Vicenza Italy). PI of the Juvenile Diabetes Research Foundation (JDRF USA) project on encapsulation of pancreatic cells. 2012: Coordinator of the Marie Curie training network BIOART for developing innovative (bio)artificial devices for treatment of kidney and liver disease. Member of the scientific commission of the Euromembrane 2012, London, UK. 2011: Guest editor of special issue on "Artificial organs and biomaterials" of the Journal of Functional Biomaterials. Member of the scientific commission of the 24 th European conference on Biomaterials, ESB 2011, Dublin Ireland. 2010: Organizer of Marie Curie course entitled: Nano-structured materials and Membranes for Health and Sustainable Water (University of Twente, 60 participants / 23 invited lecturers from all over the world) : Coordinator of the cluster: Membranes for health within the European network of Excellence NanoMemPro.

8 8 Glucocorticoid Signaling System: Clinical Implications Prof. George P. Chrousos University of Athens, Athens, Greece url: Abstract In humans, glucocorticoids regulate a broad spectrum of physiologic functions essential for life and play an important role in the maintenance of basal and stress-related homeostasis. Approximately 20% of the genes expressed in human leukocytes are regulated positively or negatively by glucocorticoids. These steroids are involved in almost every cellular, molecular and physiologic network of the organism and play a pivotal role in critical biologic processes, such as growth, reproduction, intermediary metabolism, immune and inflammatory reactions, as well as central nervous system and cardiovascular functions. Physiologic amounts of glucocorticoids are also essential for normal renal tubular function and thus for water and electrolyte homeostasis. Furthermore, glucocorticoids represent one of the most widely used therapeutic compounds often employed in the treatment of inflammatory, autoimmune and lymphoproliferative disorders. Both excess and deficiency of glucocorticoids are respectively associated with disease, i.e. Cushing syndrome or Addison disease. Hence, target tissue resistance or hypersensitivity to these hormones is also expected to be associated respectively with glucocorticoid deficiency or excess manifestations. At the cellular level, the action of glucocorticoids is mediated by an intracellular protein, the glucocorticoid receptor (GR). The human (h) GR belongs to the steroid/thyroid/retinoic acid nuclear receptor superfamily of proteins and functions as a ligand-dependent transcription factor that regulates the expression of glucocorticoid-responsive genes positively or negatively. The effector domains of the GR mediate transcriptional activation by recruiting co-regulatory multi-subunit complexes that remodel chromatin, target initiation sites, and stabilize the RNA polymerase II machinery for repeated rounds of transcription of target genes. Alternatively, the GR may act via interactions with other transcription factors, positively or negatively modulating the actions of these factors on their own target genes. Our current molecular understanding of the actions of glucocorticoids has led us to hypothesize that each individual, tissue and target gene respond differently to glucocorticoids and that one can dissociate the effects of synthetic glucocorticoids to favor several types of actions vs. others. Thus, some degree of tissue specificity of glucocorticoid actions is expected even in the presence of a single GR mutation or use of the same glucocorticoid compound. Primary glucocorticoid resistance is a rare sporadic or familial syndrome characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. Compensatory elevations in circulating adrenocorticotropic hormone (ACTH) concentrations lead to increased secretion of cortisol and adrenal steroids with mineralocorticoid and/or androgenic activity, but no clinical evidence of hypercortisolism. The clinical spectrum of the condition is broad, ranging from asymptomatic to severe cases of hyperandrogenism, fatigue (presumably a glucocorticoid deficiency manifestation) and/or mineralocorticoid excess. The condition has also been associated with female and male hypofertility, presumably as a result of hyperandrogenism and intratesticular and/or adrenal rests. One case was reported with a pituitary corticotropinoma. The molecular basis of glucocorticoid resistance has been mainly ascribed to mutations in the human glucocorticoid receptor (hgr) gene, which impair glucocorticoid signal transduction, thereby altering tissue sensitivity to glucocorticoids. The

9 9 study of functional defects of natural hgr mutants enhances our understanding of the molecular mechanisms of hgr action and highlights the importance of integrated cellular and molecular signaling mechanisms for maintaining homeostasis and preserving normal physiology. Glucocorticoid hypersensitivity is an even rarer, enigmatic condition characterized by generalized, partial, target-tissue hypersensitivity to glucocorticoids. Compensatory decreases in circulating ACTH concentrations may lead to decreased secretion of cortisol and adrenal steroids with mineralocorticoid and/or androgenic activity, but no clinical evidence of hypocortisolism. The clinical manifestations of this condition include those of glucocorticoid excess, ie, obesity and metabolic syndrome. In a single case, a woman with metabolic syndrome, a mutation of the GR causing hypersensitivity to glucocorticoids was found. Although target tissue-specific glucocorticoid resistance or hypersensitivity is a hard condition to study in humans, there are now a host of human states in which such evidence has been produced. These include several allergic, autoimmune, inflammatory and lymphoproliferative states, such as asthma, systemic lupus erythematosus, rheumatoid arhrtitis, ulcerative colitis, respiratory distress syndrome and lymphomas, in the case of resistance, and metabolic and immune states, such as AIDS-associated metabolic syndrome and immunosuppression and visceral adiposity associated metabolic syndrome in the case of hypersensitivity. These states may be associated with the many molecules that interact with the glucocorticoid signaling system and decrease or increase the actions of glucocorticoids. We and others have demonstrated many such cross-talks, which include the CLOCK, G protein, small G protein, TNFalpha, CDK5, p38 and AMPK signaling systems, as well as two accessory proteins of the HIV-1 virus, Vpr and Tat, both of which function as coactivators of the glucocorticoid receptor. Furthermore, the lethal protein of the anthrax bacterium and the E1A protein of the adenoviruses, have both been associated with the induction of glucocorticoid resistance in infected cells. The case of CLOCK-GR interactionrelated glucocorticoid hypersensitivity is particularly pertinent into explaining the negative effects of chronic stress, frequent traveling across time zones, working night shifts and taking long-acting glucocorticoids. Short CV George P. Chrousos is Professor and Chairman of the First Department of Pediatrics at the University of Athens School of Medicine, Athens, Greece, and former Chief of the Pediatric and Reproductive Endocrinology Branch of the National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland. He currently also holds the UNESCO Chair on Adolescent Health Care at the University of Athens and held the 2011 John Kluge Distinguished Chair in Technology and Society at the Library of Congress, Washington DC. Prof. Chrousos is internationally recognized for his research on the glucocorticoid signaling system of the cell, on the diseases of the hypothalamic-pituitary-adrenal axis, and on the physiological and molecular mechanisms of stress. His work has opened new horizons in our understanding of a spectrum of human complex disorders, including depression, the eating disorders, the metabolic syndrome and the inflammatory autoimmune and allergic diseases. His contributions span a range of medical disciplines, including Medicine, Pediatrics, Endocrinology, Psychiatry, Rheumatology, Allergy, Surgery, Oncology and Reproductive Medicine. Dr. Chrousos has written over 700 original scientific papers and over 500 book chapters and journal reviews and his work has been cited in more than 65,000 other scientific articles, an irrefutable testimony to the importance and influence of his research. He is one of the 250

10 10 most cited scientists internationally (ISI highly cited) included not only in the list of Clinical Medicine, but also in that of Biology and Biochemistry, and the highest cited endocrinologist and pediatrician in the world. With an H index of 129, Dr. Chrousos is a top cited Clinician and Clinical Researcher. Dr. Chrousos has received numerous national and international awards and has given many lectures in the USA, Europe, Latin America and Japan. His awards include the 1987 Richard E. Weitzman Memorial Award, US Endocrine Society, the 1992 Superior Service Award, U.S. Public Health Service, the 1997 Clinical Investigator Award, US Endocrine Society, the 1997 Hans Selye Award, Hans Selye Foundation, Montreal, Canada, the 1999 Pharmacia- Upjohn International First Prize for Excellence in Published Clinical Research, US Endocrine Society, the 1999 Novera Herbert Spector Award, International Society for Neuroimmunomodulation, Lugano, Switzerland, the 2000 Henning Andersen Prize, European Society for Pediatric Endocrinology, Brussels, Belgium, the 2002 Sir Edward Sharpey-Schafer Medal, British Endocrine Societies, the 2004 Lifetime Achievement Award, International Society for Psycho-Neuro-Endocrinology, Glasgow, UK, the 2007 Henning Andersen Prize, European Society for Pediatric Endocrinology, Helsinki, Finland, and the 2008 Geoffrey Harris Prize in Neuroendocrinology, European Society of Endocrinology, Berlin, Germany. Among others, he is a Doctor Honoris Causa of the University of Liege, Liege, Belgium (2003), Universita Politechnica delle Marche, Ancona, Italy (2006) and University of Patras, Patras, Greece (2011). He is an honorary professor of the University of Warwick, Coventry, UK. Recently, he was honored with the 2011 Aristeion Bodossaki Award, the highest distinction for accomplishment in the Sciences in Greece. In 2012, he received the Albert Struyvenberg Medal of the European Society of Clinical Investigation (ESCI). He is a distinguished visiting scientist of NICHD, NIH, Bethesda MD, USA. He served as President of ESCI from 2008 to Dr Chrousos was inducted as a Master of both the American College of Endocrinology and the American College of Physicians and a Fellow of the Royal College of Physicians, London, UK. He currently is the president of the European Society of Clinical Investigation. He is an elected member of the American Society for Clinical Research, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, Washington DC, USA, and the Academia Europaea, London, UK. Prof. Chrousos run one of the best endocrine training programs in the world and fostered the careers of over 60 distinguished, award-winning, world-class physician-scientists. After a 25 year distinguished career in the Intramural Program of the NIH, where he made seminal original contributions and trained a generation of international leaders in Endocrinology, Dr. Chrousos returned to his country and has assumed leadership roles at the University of Athens and in Greek and European Medicine and Academia.

11 11 Πέμπτη 18 Ιουλίου 2013 SESSION 2 Συντονιστής: Διευθυντής Ινστιτούτου Πυρηνικής & Σωματιδιακής Φυσικής 10:00 Fundamental Physics to 2030 challenges for Europe Prof. Themis Bowcock Dept. of Physics, Oliver Lodge Laboratory, University of Liverpool 10:30 Predicting and interpreting complex phenomena in matter through multiscale modelling Prof. Efthimios Kaxiras Dept. of Physics and School of Engineering and Applied Sciences, Harvard University

12 12 Fundamental Physics to 2030 challenges for Europe Prof. Themis Bowcock Department of Physics, Oliver Lodge Laboratory, University of Liverpool Abstract In this talk I will discuss the different challenges and programmes for Experimental Particle and AstroParticle Physics in Europe from the point of view of a University Groups. The importance to provide front rank discovery potential, invest in future training and deliver a programme that offers continuity beyond the LHC are foremost. The European Strategy Group has reported at CERN and offers clear guidance to activities at CERN. I will discuss how these relate to opportunities in North America, Asia and how we are looking at investment in, and from, new expanding economical areas. The relationship to economical impact, in my case the requirement of the UK Government, and how this will influence our long term R&D policy will also be discussed. Opportunities for international and bilateral collaborations are outlined. Short CV Themis Bowcock is currently Head of the Liverpool group, one of the biggest groups in the UK, with over 15M of funding and 70 staff. The Liverpool group has established presence on the ATLAS, LHCb, NA62, T2K and SNO+ experiments. He was educated at New College, Oxford and Queen Mary College, London where he was awarded his PhD on the UA1 experiment. He is a co-author on the discovery of the W and Z bosons which unified the Electric and Weak forces. He worked in the US for 8 years first as a post-doctoral fellow at Harvard University and then moved to the Super Conducting Super Collider as one of its first fellows, and was also an Assistant Professor of Physics at Texas A&M. From 1991 he worked at Liverpool University on the LEP experiment DELPHI working on B- lifetimes and tri-linear gauge couplings. In 2000 he was responsible for building one of the world s first commodity supercomputers (MAP) and its replacement MAP2 that reached the top 100. In 2003 he was co-founder and technical director of the 10M AiMeS Institute which was focused on commercial exploitation of new Grid Technologies. This delivered several innovations and entrepreneur awards as well numerous spin-off companies. Themis originated and led the LHCb Vertex Detector project in the UK from 1997 onwards with Liverpool building all the VELO modules. He is currently leading the UK to build the VELO pixel replacement for His physics interests include work on top decays at LHCb. In 2013 he joined the g-2 experiment at Fermilab, aimed at making the world s most precise measurement of the muon g, and EDM. Themis serves on the UK STFC CLASP committee (Challenge Led Applications) and for several years was the PP representative on the UK STFC Innovations and Partnerships schemes. Both committees are the primary source of funding for industry and PP research in the UK. Contact: Professor Themis Bowcock Head of Particle Physics Department of Physics Oliver Lodge Laboratory Oxford Street, Liverpool, L69 7ZE, UK bowcock@liverpool.ac.uk

13 13 Predicting and interpreting complex phenomena in matter through multiscale modeling Prof. Efthimios Kaxiras John Hasbrouck Van Vleck Professor of Pure and Applied Physics Department of Physics and School of Engineering and Applied Sciences, Harvard University, Cambridge MA 02138, USA Abstract The behavior of matter at various length and time scales is key to understanding mechanical, optical and electronic properties, which are the core of most technological applications. This behavior can only be captured by methods that incorporate several scales simultaneously, in order to predict and interpret complex phenomena that range from brittle fracture to the efficiency of photosynthesis. In this talk we will review some key concepts in formulating multiscale modeling methods and will emphasize the application of these methods to several cases of interest, such as non-newtonian blood flow, and the use of layered materials for novel optoelectronic devices. Short CV Professor Efthimios Kaxiras started his academic education at the National Technical University of Athens and continued at the Massachusetts Institute of Technology where he received his PhD in theoretical physics. He is currently the John Hasbrouck Van Vleck Professor of Pure and Applied Physics, and the Director of the Institute for Applied Computational Science at Harvard University. He has been a Visiting Faculty at ETH-Zurich, EPF-Lausanne, the University of Ioannina and the University of Crete. He has also served as Director of Harvard s Initiative in Innovative Computing and Associate Director of the Materials Science and Engineering Center. He holds several distinctions such as Fellow of the American Physical Society and Chartered Physicist and Fellow of the Institute of Physics (London). He serves on the Editorial Board of several scientific journals and has published widely in the area of computational materials science with emphasis on multiscale simulations and on complex physical phenomena ranging from brittle-vs.-ductile behavior of solids, to the translocation of biomolecules and their interaction with nanostructured substrates.

14 14 Πέμπτη 18 Ιουλίου 2013 SESSION 3 Συντονιστής: Διευθυντής Προηγμένων Υλικών, Φυσικοχημικών Διεργασιών, Νανοτεχνολογίας & Μικροσυστημάτων 11:30 The role and the impact of a Private Public Partnership R&D Center in Switzerland and beyond its borders Dr. Georges Kotrotsios Vice President Marketing and Business Development, Member of the Executive Board 12:00 Leading research institutions: an EU-funded opportunity for an innovation jump in Greece Dr. Odysseas Cartalos Management Consulting Director, LOGOTECH 12:30 The New Argonauts and Network Innovation Prof. Dimitris Assimakopoulos Grenoble École de Management, LINC Lab

15 15 The role and the impact of a Private Public Partnership R&D Center in Switzerland and beyond its borders G. Kotrotsios CSEM SA, Jaquet Droz 1, CH 2002, Neuchâtel, Switzerland gko@csem.ch Abstract Switzerland for several years now is ranking world s number 1 in European innovation scoreboards; it is generally accepted that such leadership plays an important role in the overall positive outlook of the country. We will try to outline the key factors behind the Swiss innovation system, mutual interactions between actors, support measures, strengths and weaknesses. Among the key actors of the Swiss system we can find three major RTOs (Research and Technology Organization); CSEM, a private public partnership, is one of these three organizations. We will attempt to outline the modus operandi of CSEM as well as its impact on the national economy and the society. Then, we will try to identify the elements which could be transposed to Greece. During the last ten years, efforts have been deployed to transpose and export CSEM s model, in some cases with nice successes, as for instance in Brazil, but also failures in other cases. We will summarize, the most relevant lessons learned in the framework of these endeavors. Further, a brief analysis of CSEM s international R&D cooperation links will help to deepen the insight on constraints and drivers of technological innovation under different economic environments. Our presentation has a dual objective: first, to stimulate the discussion on what can be efficient technological research and innovation practices and second to underline the fact that efficient and performing RTO s and Technical Universities, actively interacting between them and clearly oriented towards international industry, can be a motor of progress, even in our country were financial resources are and will be limited. Switzerland for several years now is ranking world s number 1 in European innovation scoreboards; it is generally accepted that such leadership plays an important role in the overall positive outlook of the country. We will try to outline the key factors behind the Swiss innovation system, mutual interactions between actors, support measures, strengths and weaknesses. Among the key actors of the Swiss system we can find three major RTOs (Research and Technology Organization); CSEM, a private public partnership, is one of these three organizations. We will attempt to outline the modus operandi of CSEM as well as its impact on the national economy and the society. Then, we will try to identify the elements which could be transposed to Greece./During the last ten years, efforts have been deployed to transpose and export CSEM s model, in some cases with nice successes, as for instance in Brazil, but also failures in other cases. We will summarize, the most relevant lessons learned in the framework of these endeavors. Further, a brief analysis of CSEM s international R&D cooperation links will help to deepen the insight on constraints and drivers of technological innovation under different economic environments./ Our presentation has a dual objective: first, to stimulate the discussion on what can be efficient technological research and innovation practices and second to underline the fact that efficient and performing RTO s and Technical Universities, actively interacting between them and clearly oriented towards international industry, can be a motor of progress, even in our country were financial resources are and will be limited. Short CV George Kotrotsios holds a Ph.D. Degree in Optoelectronics, Institut National Polytechnique de Grenoble (Fr), an Executive MBA in Management of Technology, HEC, Université de

16 Lausanne (CH) and an Electrical Engineering Degree from the Aristotle University of Thessaloniki (Gr). In CSEM SA, a major Swiss Research and Innovation center, he conducted several years applied R&D in the field of optical fiber communications and sensors as well on fiber manufacturing technology, fiber lasers, surface engineering, nanotechnologies (having developed the first commercial European Atomic Force Microscope - AFM), since Between 1996 and 1999, he was with M3D SA, a contract research organisation, a joint venture of Mitsubishi Co and Battelle. He developed then two start-ups in optical communications and sensors. He joined again CSEM at the end of 1999 He is in charge of the Marketing and Business Development of the company since April From January 1st, 2010 he is in member of the Executive Board of CSEM, in charge of Business Development, Technology Commercialization and Strategic Relations, including European Commission and European Space Agency. Presently, he is - member of the Executive Board of EARTO (the European Association of Research and Technology Organizations), - member of the Board of Directors of CSEM do Brazil, - member of the Experts Committee of Micronarc, the Microsystem and Association in Western Switzerland, - member of the Board of the HTA (Heterogeneous Technology Alliance, the Alliance of CEA-LETI, VTT, Fraunhofer Microelectronics Association) and CSEM); he assumed the rotating presidency in G. Kotrotsios was chairman of the Board of Directors of Sensecore (company active in wearable electronics for elite athletes) up to the successful second round of investment. 16

17 17 Leading research institutions: an EU-funded opportunity for an innovation jump in Greece Dr. Odysseas Cartalos LOGOTECH, 100, Kifisias avenue and 83, Marathonoromou street, GR Marousi, Athens Abstract A new element in Horizon 2020 is the teaming competition scheme. The scheme will offer substantial funding on a competitive basis for projects aiming to develop cutting-edge research centres in less advanced EU regions. The proposals for funding are submitted by teams comprising (a) an internationally recognised research institute and (b) the hosting region. A recent study for the European Parliament by the present author drew attention to the urgent need for Europe to increase its attractiveness for the world top scientists. The associated challenge is for the EU and its member states to re-enter the worldwide competition in science and technology against established and new fast-rising regional players. The teaming competition was identified as one of few measures that would adequetely serve such objective, provided that the accent is placed on creating the conditions for top performers to relocate and develop an innovation-conducive environment in the less advanced regions. With this perspective, the scheme is crucial for Greece, as it offers a concrete opportunity for the country to boost its innovation capacity and create conditions for knowledge-based growth. Major assets of Greece in the long and tedious effort to actually obtain funding and launch a leading research center are its current research potential, its culture and living conditions, as well as its distiguished diaspora. The presentation will discuss key parameters that need to be taken into account for designing a viable project under the teaming competition scheme, which include: the focus on high-quality research, the funding perspectives for long-term and high-risk research, the flexibility in terms of hiring highly-qualified and promising researchers, as well as the governance principles that set the ground for success. Short CV Odysseas Cartalos has earned a PhD in Chemical Engineering and a Habilitation from the Institut National Polytechnique of Grenoble, France. He has worked for about 10 years as research manager in the oil and gas industry, then moved to consulting, where he acquired senior practical experience in ICT, Public Administration and HR Management. He has led major assignments for the European Parliament, the European Commission and other institutions and government bodies involved in policy making. He was particularly involved in the design, implementation and evaluation of interventions in Research and Innovation in the framework of European initiatives, including FP7, CIP and Horizon 2020, as well as of Structural Funds. Dr. Cartalos has authored 35 scientific publications, 2 patents and a large number of consulting studies and reports.

18 18 The New Argonauts and Network Innovation Professor Dr. Dimitris Assimakopoulos Founder & Director LINC Lab, Grenoble Ecole de Management Vice- President, EDAMBA Abstract Nurturing innovation, technological and/or organizational, it is of growing significance in an era of creative destruction and glo-calization. The role of new Argonauts for strengthening innovation and thus competitiveness, in regional economies as far apart, as Silicon Valley, Bangalore and Tel Aviv, it has been highlighted as a key factor in reversing brain drain to brain circulation (Saxenian, 2006). Network innovation based on returnees and new Argonauts, create a win-win for advanced and less advanced knowledge economies in entrepreneurial regions around the globe (Assimakopoulos et al, 2011). To what extent however, there are returnees in Greece empowered to up start businesses or reverse the current brain drain? The Greek diaspora is as important in terms of intellectual strength as the Jewish one. What holds back the Greek diaspora for boosting innovation? And, what are the lessons to be learned from best practices of networks of innovators, mostly returnees, who can bridge large geographical distances, setting the example to follow, say, in the case of Israel, near to Greece. Implications for further research, policy and practice are also going to be discussed based on ongoing research in the regional innovation ecosystem in Grenoble, France. References Assimakopoulos D, Carayannis E., and Dossani, R. (Eds.), 2011, Knowledge Perspectives of New Product Development: a Comparative Approach, New York: Springer. Saxenian, A., 2006, The New Argonauts: Regional Advantage in a Global Economy, Cambridge, MA.: Harvard University Press Short CV Assimakopoulos is a Professor of Information Systems & Technology Management, Founding Director of the LINC (Learning & Innovation in Networks & Communities) Lab, at the triple accredited: AACSB, EQUIS and AMBA, Grenoble Ecole de Management (GEM) in France. He is also the Founding Director of the GEM joint Doctorate of Business Administration program with the Newcastle University (UK) and serves as the Vice-President of the European Doctoral programs Association in Management & Business Administration (EDAMBA). Assimakopoulos studied at the Universities of Patras, Sheffield, Grenoble and Stanford. He holds an HDR in Economics from the University Pierre Mendes France (Grenoble 2); a PhD and Masters in Architectural Studies from the University of Sheffield, England; and a Diploma in Civil Engineering from the University of Patras, Greece. He was also twice a Visiting Scholar in Economic Sociology at Stanford University, California. The focus of his research is on the emergence of new technological communities and networks of practice across organizational and national boundaries shaping innovation processes; and, informal collaboration networks fostering learning and innovation in emerging technologies in the EU, Silicon Valley and China. His research monograph on Technological Communities and Networks: Triggers and Drivers for Innovation was published by Routledge in 2007 (translated in Chinese and published by Tsinghua University Press in 2010); co-edited: 'Innovation Networks and Knowledge Clusters' published by Palgrave in 2008; Knowledge Perspectives of New Product Development published by Springer in 2011; and Management of Emerging Technologies for Socio- Economic Impact to be published by Edward Elgar in 2014; also co-editing as the founding

19 19 editor the Intl. Journal of IT and Management, published by Inderscience, since 2002; serves on the Editorial Board of Prometheus: Critical Studies in Innovation published by Routledge. His research has also appeared in scholarly journals such as Environment and Planning B, Innovation Management, Policy and Practice, International Journal of Technology Management, International Small Business Journal, Knowledge-based Innovation in China, MIT Sloan Management Review, Organizational Dynamics, Prometheus, R&D Management, and Science & Pubic Policy. Dimitris was the recipient of a European Commission (EC) Marie Curie fellowship under the Human Capital and Mobility program. For the past twenty years, he was invited to consult private companies, such as the ARM, STMicroelectronics and EADS; manage externally funded projects and present his research in specialist meetings organised by the EC (DGs Industry & Information Society), European Science Foundation, European Institute for Advanced Studies in Management, European Academy of Management, European Organisation for Nuclear Research (CERN), British Academy of Management, Economic and Social Research Council in the UK, National Centre for Scientific Research (CNRS) in France, Strategic Research Council in Denmark, and the US National Science Foundation Dimitris Assimakopoulos, PhD, HDR Professor of Technology Management Grenoble Ecole de Management, LINC Lab 12 rue Pierre Semard, BP 127, Grenoble 38003, France dimitris.assimakopoulos@grenoble-em.com.

20 20 Πέμπτη 18 Ιουλίου 2013 SESSION 4 Συντονιστής: Διευθυντής Ινστιτούτου Πληροφορικής & Τηλεπικοινωνιών 14:30 Kernel methods with imbalanced data and applications Prof. Theodore B. Trafalis School of Industrial Engineering, Univ. of Oklahoma Director of the Laboratory of Optimization and Intelligent Systems 15:00 Extracting Geospatial Information from Social Media Feeds Prof. P. Aggouri, Chair, Dept. of Geography & Geoinformation Science, George Mason University Assoc. Prof., Α. Stefanidis, Dept. of Geography & Geoinformation Science, Center for Geospatial Intelligence, George Mason University 15:30 Real time considerations in the localization and control of epileptic seizures Dr. Kostas Tsakalis Professor and Associate Director of Infrastructure, Dept. of Electrical, Computer and Energy Engineering, Arizona State University